ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 396
A Comparison of the Illness Experience Reported Via the Patient Reported Outcomes Measurement Information System Between Patients with Childhood-Onset Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, and Widespread Chronic Musculoskeletal Pain
9:00AM-11:00AM
Abstract Number: 405
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 410
Characteristics of the Juvenile Systemic Sclerosis Cohort within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
9:00AM-11:00AM
Abstract Number: 408
Characterization of Pediatric Systemic Lupus Erythematosus with Acquired Angioedema
9:00AM-11:00AM
Abstract Number: 386
Chronic Arthritis in Systemic Lupus Erythematosus: Distinct Features in 336 Pediatric and 1,830 Adult Patients
9:00AM-11:00AM
Abstract Number: 421
Clinical Analysis and Outcome of Interstitial Lung Disease with Juvenile Dermatomyositis
9:00AM-11:00AM
Abstract Number: 389
Clinical and Serological Differences Between Juvenile-Onset and Adult-Onset Systemic LUPUS Erythematosus Patients from a National Registry of Patients
9:00AM-11:00AM
Abstract Number: 398
Clinical and Serological Profile of Children with Positive SSA-Ro/SSB-La Antibodies
9:00AM-11:00AM
Abstract Number: 394
Clinical Features of Children with Silent Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 391
Current Provider Practices and Perceived Barriers for Mental Health Care of Adolescents with SLE
9:00AM-11:00AM
Abstract Number: 395
Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up
9:00AM-11:00AM
Abstract Number: 420
Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
9:00AM-11:00AM
Abstract Number: 419
Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis
9:00AM-11:00AM
Abstract Number: 415
Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)
9:00AM-11:00AM
Abstract Number: 400
Disease Activity and Health Care Utilization Among Young Adults with Childhood-Onset Lupus Transitioning to Adult Care: Data from the Pediatric Lupus Outcomes Study
9:00AM-11:00AM
Abstract Number: 409
Disease Activity, Disease Damage and Predictive Factors in Juvenile Onset Mixed Connective Tissue Disease – a Norwegian Nationwide Study
9:00AM-11:00AM
Abstract Number: 387
Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study
9:00AM-11:00AM
Abstract Number: 393
From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients
9:00AM-11:00AM
Abstract Number: 392
From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
9:00AM-11:00AM
Abstract Number: 417
Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 425
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
9:00AM-11:00AM
Abstract Number: 423
Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database
9:00AM-11:00AM
Abstract Number: 407
Inter-Observer Variability of the Histological Classification of Lupus Glomerulonephritis in Children
9:00AM-11:00AM
Abstract Number: 413
Is There a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerosis in Childhood? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com
9:00AM-11:00AM
Abstract Number: 406
Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis
9:00AM-11:00AM
Abstract Number: 404
Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 397
Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus
9:00AM-11:00AM
Abstract Number: 424
Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of  Cardiac Involvement in Juvenile Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 399
Management of Lupus Anticoagulant Hypoprothrombinemia Syndrome in Juvenile Systemic Lupus Erythematosus – Single Center Experience
9:00AM-11:00AM
Abstract Number: 422
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
9:00AM-11:00AM
Abstract Number: 388
Pain, Fatigue and the Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus
9:00AM-11:00AM
Abstract Number: 411
Patient Reported Outcomes in Juvenile Dermatomyositis: Assessing the Importance of Different Measures to Patients and Families
9:00AM-11:00AM
Abstract Number: 414
Performance of the Adult Systemic Sclerosis Classification in Juvenile Systemic Sclerosis Patients. Results from the Juvenile Systemic Sclerosis Inception Cohorte Www.Juvenile-Scleroderma.Com
9:00AM-11:00AM
Abstract Number: 402
Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 416
Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort
9:00AM-11:00AM
Abstract Number: 403
Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?
9:00AM-11:00AM
Abstract Number: 401
Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample
9:00AM-11:00AM
Abstract Number: 418
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
9:00AM-11:00AM
Abstract Number: 426
The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
9:00AM-11:00AM
Abstract Number: 390
Treatment and Outcomes in Pediatric SLE Patients in South Africa
9:00AM-11:00AM
Abstract Number: 412
Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 50 Patients at First Assessment. Www.Juvenile-Scleroderma.Com
9:00AM-11:00AM
Abstract Number: 385
Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology